Swiss drug development company Relief Therapeutics Holdings SA (Relief Therapeutics)(SWX:RLF) said on 23 September 2020 that along with its US partner NeuroRx, it has asked the US Food and Drug Administration for emergency approval for a drug it aims to repurpose against COVID-19, Reuters news agency reported on Wednesday.
Citing a 51-person study, Relief Therapeutics said in a statement: "Patients treated with RLF-100 demonstrated a three-fold advantage in survival, recovery from respiratory failure and other parameters indicative of meaningful clinical improvement."
The company added that the request, if granted, would make the drug, previously used against conditions including erectile dysfunction, available to those in intensive care who have exhausted all approved treatments.
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain